Allworth Financial’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$58.6K Buy
782
+22
+3% +$1.41K ﹤0.01% 2343
2026
Q1
$42.8K Buy
760
+14
+2% +$912 ﹤0.01% 2435
2025
Q4
$59.8K Buy
746
+594
+391% +$39.9K ﹤0.01% 2082
2025
Q3
$7.41K Sell
152
-146
-49% -$9.04K ﹤0.01% 3319
2025
Q2
$22.2K Buy
298
+180
+153% +$11.9K ﹤0.01% 2452
2025
Q1
$7.31K Sell
118
-1,151
-91% -$78.3K ﹤0.01% 2568
2024
Q4
$93.1K Buy
1,269
+21
+2% +$1.69K ﹤0.01% 1299
2024
Q3
$100K Sell
1,248
-7
-0.6% -$566 ﹤0.01% 1088
2024
Q2
$111K Buy
1,255
+220
+21% +$19.4K ﹤0.01% 1038
2024
Q1
$88.3K Buy
1,035
+959
+1,262% +$75.3K ﹤0.01% 1064
2023
Q4
$6.5K Buy
76
+7
+10% +$605 ﹤0.01% 2162
2023
Q3
$6.18K Buy
69
+40
+138% +$3.57K ﹤0.01% 2021
2023
Q2
$2.47K Hold
29
﹤0.01% 2393
2023
Q1
$2.4K Sell
29
-2
-6% -$162 ﹤0.01% 2332
2022
Q4
$2.44K Hold
31
﹤0.01% 2171
2022
Q3
$2K Buy
31
+16
+107% +$1.15K ﹤0.01% 2149
2022
Q2
$1K Buy
15
+8
+114% +$473 ﹤0.01% 2165
2022
Q1
$0 Buy
+7
New +$381 ﹤0.01% 2219

Other funds holding HAE

Allworth Financial's HAE Position: Q2 2026 in Review

Allworth Financial increased its Haemonetics (HAE) stake by 2.9% in Q2 2026, buying an estimated $1.41K and bringing the position to 782 shares worth $58.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2343.

Allworth Financial first reported a position in HAE in Q1 2022 and has held it in 18 quarters since. The position peaked at $111K in Q2 2024. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Allworth Financial held 782 shares of Haemonetics worth $58.6K as of Q2 2026.
  • Allworth Financial bought 22 Haemonetics shares in Q2 2026, an estimated $1.41K.
  • Haemonetics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2343 holding.
  • Allworth Financial first reported a position in Haemonetics in Q1 2022 and has held it in 18 quarters since.
  • Allworth Financial's Haemonetics position peaked at $111K in Q2 2024.
  • 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.